Welcome to our dedicated page for MINIMED GROUP SEC filings (Ticker: MMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MINIMED GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MINIMED GROUP's regulatory disclosures and financial reporting.
MiniMed Group, Inc. Chief Executive Officer Dallara Que reported a routine tax-related share disposition. On this Form 4, 4,809 shares of Common Stock were withheld by the company at $16.31 per share to cover income tax obligations tied to vesting RSUs. After this withholding, Que directly holds 616,754 shares, and the filing notes that this total includes shares to be issued upon future RSU vesting.
MiniMed Group, Inc. adopted a new Severance Pay Plan for Executives and a Change of Control Severance Plan for its named executive officers. Executives at vice president level and above become eligible for severance after certain terminations if they sign a release of claims and meet plan conditions.
For eligible terminations not tied to a change of control, each named executive officer may receive a lump-sum cash payment equal to two times annual base salary plus target bonus, and a lump-sum equal to 24 months of medical and dental COBRA premiums. Equity awards generally do not continue vesting unless the executive is retirement-eligible.
Following a change of control, each named executive officer is promised three years of employment on terms no less favorable than those in place beforehand. If they are terminated without cause or resign for good reason during that period, they may receive a pro-rated annual bonus, a lump sum equal to three times base salary plus the highest recent annual bonus, three additional years of credited retirement benefits, and three years of continued health and life insurance benefits. The plan also includes a mechanism to adjust benefits if excise taxes under Section 4999 of the Internal Revenue Code would apply.
MiniMed Group, Inc. announced that the U.S. Food and Drug Administration has cleared the MiniMed Flex™, a next-generation, discreet, smartphone-controlled insulin pump. The clearance came several months earlier than anticipated and will allow earlier commercialization of this key product.
Development of MiniMed Flex™ was funded in part by affiliates of Blackstone Life Sciences Advisors L.L.C. Under their agreement, during the first two years following U.S. regulatory approval and commercial launch, Blackstone will receive the greater of a mid-to-high single digit royalty percentage on applicable net sales or a minimum payment of $157 million. MiniMed expects to recognize a one-time charge of $157 million in the fourth quarter of fiscal year 2026 related to these future payments.
MiniMed Group, Inc. officer John Gyurci reported receiving 15,322 shares of common stock on a grant or award basis, with no cash price per share. These shares represent restricted stock units in MiniMed that were created by converting prior Medtronic equity awards in connection with MiniMed’s separation from Medtronic.
The units were granted under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest in three equal installments on January 26, 2027, January 26, 2028, and January 26, 2029. Following this equity award conversion, Gyurci directly holds 15,322 MiniMed shares, including shares to be issued upon future vesting of restricted stock units.
MiniMed Group, Inc. insider Chandrasena Gillian reported multiple grants of common stock on March 11, 2026, all classified as awards rather than market purchases. Each grant reflects MMED restricted stock units received at a price of $0.00 per share.
According to the footnotes, these MMED RSUs were issued when certain Medtronic plc equity awards held by the insider were converted into MiniMed awards in connection with the company’s separation from Medtronic effective March 9, 2026, under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The converted RSUs vest over time, with tranches scheduled between July 28, 2026 and July 28, 2028, making this a compensation-related equity conversion, not an open‑market stock trade.
MiniMed Group, Inc. reported a compensation-related stock grant to officer Wills Courtney Nelson tied to the company’s separation from Medtronic. On March 11, 2026, Nelson received several awards of MiniMed common stock as part of the conversion of prior Medtronic equity awards into MiniMed restricted stock units under the 2026 Long Term Incentive Plan.
The awards were granted at $0.00 per share and represent time-vesting RSUs that will settle in MiniMed shares as they vest. According to the footnotes, these RSUs result from an equity award conversion process using average trading prices of both Medtronic and MiniMed shares, with vesting dates ranging from July 31, 2026 through April 28, 2028.
MiniMed Group, Inc. reported that officer Dianaty Ali received multiple grants of common stock on March 11, 2026, all with a grant price of $0.00 per share. These are classified as awards rather than open-market purchases.
The grants represent MMED restricted stock units created when prior Medtronic restricted and performance share awards were converted following MiniMed’s separation from Medtronic effective March 9, 2026, under an Employee Matters Agreement. The MMED RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on several dates between July 31, 2026 and October 29, 2028, including single-date vesting and a three-installment schedule.
MiniMed Group, Inc. EVP and Chief Financial Officer Chad Spooner received multiple equity awards in connection with MiniMed’s separation from Medtronic plc. On March 11, 2026, he was granted time-vesting restricted stock units (MMED RSUs) that were created by converting prior Medtronic restricted stock and performance share awards under an Employee Matters Agreement tied to the March 9, 2026 separation.
The grants cover 70,896 shares vesting on April 28, 2028, 127,609 shares vesting in three equal installments on July 28, 2026, July 28, 2027 and July 28, 2028, and 70,896 shares vesting on July 28, 2028. All awards were issued at a reported price of $0.00 per share as compensation, not as open-market purchases or sales, and were made under the 2026 MiniMed Group, Inc. Long Term Incentive Plan.
MiniMed Group, Inc. reported that Chief Executive Officer Dallara Que received multiple equity awards in the form of MiniMed common stock–denominated restricted stock units on March 11, 2026. These awards were granted at a price of $0.00 per share as compensation, not through open-market purchases.
The footnotes explain that existing Medtronic restricted stock units and performance share units held by Que were converted into MiniMed RSUs in connection with MiniMed’s separation from Medtronic plc, under an Employee Matters Agreement. The converted RSUs were issued under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest on various dates between July 31, 2026 and April 28, 2028, with one grant vesting in two installments on March 10, 2026 and March 10, 2027.
MiniMed Group, Inc. director Timothy A. Wicks reported an acquisition of 13,889 shares of common stock through a grant of restricted stock units. These units vest on the one-year anniversary of the grant date rather than being immediately transferable.
After this award, Wicks is shown as directly holding 13,889 shares, which include shares to be issued upon the future vesting of one or more restricted stock units. The transaction reflects equity-based compensation rather than an open-market purchase.